Development of recommendations for the use of venoactive drugs in the treatment of chronic venous disease - where they are effective and where they are not [0.03%]
静脉活性药物治疗慢性静脉疾病临床应用专家建议的制订——有效的方面和不推荐的方面
Dalibor Musil
Dalibor Musil
The article provides an overview of the development of recommendations for indications of venoactive drugs for treating symptoms and signs associated with chronic venous disease (CVD). Venoactive drugs may be beneficial in patients with sub...
Viktor Klementa,Naděžda Petejová,Josef Zadražil et al.
Viktor Klementa et al.
One of the common causes of acute kidney injury (AKI) is drug nephrotoxicity. A large group of drugs associated with AKI includes a considerable number of antimicrobials. Clinical manifestations range from mild forms of tubular damage to si...
Prevention and treatment of cancer associated venous thromboembolism - interdisciplinary consensus [0.03%]
癌症相关静脉血栓栓塞的预防和治疗：学科间共识
Ivar Vacula,Zuzana Rusiňáková,Denisa Čelovská et al.
Ivar Vacula et al.
The increasing volume of the data and experience with direct oral anticoagulants (DOACS) in the primary and secondary prevention of venous thromboembolism in oncologic patients (CAVTE) has recently lead to changes in several international g...
Neo/adjuvant immunotherapy in the treatment of nonsmall cell lung cancer [0.03%]
新辅助和辅助免疫治疗在非小细胞肺癌中的应用
Martin Svatoň,Jiří Blažek,Marcela Burešová et al.
Martin Svatoň et al.
Despite improvements in staging, surgical techniques, and the introduction of adjuvant chemotherapy for stage II and III nonsmall cell lung cancer (NSCLC), a large number of operated patients have recurrences of the disease. Due to the brea...
Antifibrotic therapy and its indications for interstitial pulmonary fibrosis [0.03%]
抗纤维化疗法及其在间质性肺纤维化中的应用指示
Martina Doubková
Martina Doubková
Idiopathic pulmonary fibrosis and chronic fibrotic interstitial lung disease with progressive phenotype are characterized by fibrotic lung parenchyma. Current antifibrotic treatment does not affect pre-existing lung parenchyma fibrosis, but...
Eliška Sovová,Samuel Genzor,Milan Sova et al.
Eliška Sovová et al.
COVID-19 pandemic has massive impact on the whole world, lead to the death of milions of people and required excessive restrictions with large economical, psychological and other impacts. Post-COVID syndrome is defined according to the Czec...
Petr Drenko,Petra Přenosilová,Alena Lavičková
Petr Drenko
Acquired von Willebrand syndrome (AvWS) is a rare bleeding disorder caused by von Willebrand factor (vWF) dysfunction of various types and severities. Clinical manifestations and differences in the intensity of bleeding are then given by th...
Case Reports
Vnitrni lekarstvi. 2022 Fall;68(E-4):16-19. DOI: 2022
The position and importance of pharmacovigilance in the Czech Republic and in the world [0.03%]
捷克和世界药品警戒的地位与重要性
Petra Zatovkaňuková,Jiří Slíva
Petra Zatovkaňuková
Pharmacovigilance is an integral part of medicine. There is always a risk of side effects when using medication; these can be completely trivial, but there are side effects that can be life-threatening or fatal. Pharmacovigilance practices ...
Recurrent urinary tract infections in kidney transplant patients with polycystic kidneys [0.03%]
多囊肾患者肾移植后的复发性尿路感染
Marcel Čellár,Martina Konko Ová,Eva Lacková et al.
Marcel Čellár et al.
Introduction: Kidney transplantation is now a routine method used to treat end-stage renal disease. About 10 % of kidney transplant patients are patients with autosomal dominant polycystic kidney disease (ADPKD). After su...
Dyslipidemia and PCSK9 inhibitors - practical focused update of indication and reimbursement criteria [0.03%]
血脂异常与PCSK9抑制剂——适应症及报销指征实用更新要点
Vladimír Soška
Vladimír Soška
PCSK9 inhibitors are modern and effective hypolipidemic drugs for lowering LDL-cholesterol, which belong to the „biological therapy“. Their prescription is limited to specialized centers and to the fulfillment of other condition...